Galapagos And Adaptimmune Enter Clinical Collaboration To License Next-Generation TCR T-Cell Therapy For Cancer Using Decentralized Manufacturing Platform
Galapagos And Adaptimmune Enter Clinical Collaboration To License Next-Generation TCR T-Cell Therapy For Cancer Using Decentralized Manufacturing Platform
加拉帕戈斯和Adaptimmune進入臨床合作，使用分散式製造平台許可下一代TCR T細胞療法治療癌症
- Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer
- Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform
- Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development
- Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales
- Galapagos has been granted an option to exclusively license uza-cel for global development and commercialization in head & neck cancer, and potential future solid tumor cancer indications
- Adaptimmune 和 Galapagos 將進行臨床概念驗證試驗，以評估在加拉帕戈斯去中心化製造平台上生產的 uza-cel（下一代 MAGE-A4 TCR T 細胞療法）對頭頸癌患者的安全性和有效性
- 在使用Adaptimmune集中製造平台進行的一期試驗中，Uza-Cel在頭頸部癌症方面顯示出令人鼓舞的結果，迄今爲止，有五分之四的患者出現了部分反應
- 初始的 體外 對加拉帕戈斯去中心化製造平台上生產的uza-cel的測試顯示，令人鼓舞的數據支持進一步的臨床開發
- Adaptimmune將獲得1億美元的初始付款，包括7,000萬美元的預付款和3000萬美元的研發資金、高達1億美元的期權行使費、最高4.65億美元的額外開發和銷售里程碑付款，外加淨銷售額的分級特許權使用費
- 加拉帕戈斯已獲准獨家許可 uza-cel，用於頭頸癌以及未來潛在實體瘤癌適應症的全球開發和商業化
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。